Treatment options for patients with obesity are associated with gastrointestinal side effects, though GLP-1 receptor agonists can also cause pancreatitis, whereas NB-ER can lead to seizures [11,54,57]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.